Vista Pharmaceuticals Reports Q3 Loss of Rs. 838.25 Lakhs, Recognizes ECL of INR 205.43 Lakhs

Vista Pharmaceuticals Ltd. has reported its unaudited financial results for the quarter and nine months ended 31st December 2025. The company's total revenue for the current quarter is Rs. 241.82 Lakhs, a decrease from Rs. 255.50 Lakhs in the corresponding quarter of the previous year. The company has recognized a provision for Expected Credit Loss (ECL) amounting to INR 205.43 lakhs against its long-pending trade receivables. The company has incurred a net loss for the quarter ended 31st December amounting to Rs. (838 25) Lakhs, resulting in a Basic Earnings Per Share (EPS) of * (1.05) per equity share. The company has outstanding statutory liabilities which have not been paid as on the quarter end, including Tax Deducted at Source (TDS) payable, Employees’ State Insurance payable, Professional Tax payable, Provident Fund payable, and Income Tax payable. The company intends to clear these dues in subsequent periods.